2016

  • Johan Blakkisrud, Ayca Løndalen, Anne Catrine Trægde Martinsen, Jostein Dahle, Jon Erik Holtedahl, Tore Bach-Gansmo, Harald Holte, Arne Kolstad, Caroline Stokke. Tumor Absorbed Dose for non-Hodgkin’s Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan. J Nucl Med jnumed.116.173922.
    Download PDF link from journal here.           Download PDF here.
     
  • Johan Blakkisrud, Ayca Løndalen, Jostein Dahle, Simon Turner, Harald Holte, Arne Kolstad, and Caroline Stokke. Red Marrow Absorbed Dose for non-Hodgkin’s Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan. J Nucl Med jnumed.116.180471 published ahead of print September 1, 2016
    Download PDF link form journal here.          Download PDF here.


2015

  • Ada H. V. Repetto-Llamazares, Roy H. Larsen, Sebastian Patzke, Karianne G. Fleten, David Didierlaurent, Alexandre Pichard, Jean Pierre Pouget, Jostein Dahle Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS One. 2015 June 11, 2015, 10.1371/journal.pone.0128816
    Download PDF link from journal here.


2014

  • Repetto-Llamazares, A., Larsen, R.H., Giust,i A.M., Riccardi, E., Bruland, O.S., Selbo, P.K., Dahle J.
    177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice. PLoS One. 2014 Jul 28; 9(7):e103070. doi: 10.1371/journal.pone.0103070. eCollection 2014.
    Download PDF link from journal here.
  • Repetto-Llamazares, A., Abbas, N., Bruland, Ø.S., Dahle, J., Larsen R.H. 
    Advantage of Lutetium-177 versus Radioiodine Immunoconjugate in Targeted Radionuclide Therapy of B-cell Tumors. Anticancer Research. 2014 Jul; 34(7), 3263-9.
    Download PDF link from journal here.

2013

  • Dahle, J., Repetto-Llamazares, A., Mollatt, C.S., Melhus, K.B., Bruland, Ø.S., Kolstad, A., Larsen, R.H.
    Evaluating Antigen Targeting and Anti-Tumor Activity of a New Anti-CD37 Radioimmunoconjugate Against Non-Hodgkin Lymphoma. Anticancer Research. (2013). 33(1), 85-95.
    Download PDF link from journal here.
  • Repetto-Llamazares, A., Larsen, R.H., Mollatt, C.S., Dahle, J.
    Biodistribution and dosimetry of 177Lu-tetulomab a new radioimmunoconjugate for treatment of Non-Hodgkin Lymphoma. Current Radiopharmaceuticals. (2013). 6(1), 20-27.
    Download PDF link from journal here.